Interpreting prospective ctDNA trials

Thoughts on RASolute 302 (for 20 minutes)

RASolute 302:https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

ADC Sequencing and the "Sandwich" method

What we do and do not understand about antibody drug conjugate sequencing. Journal of Thoracic Oncology: https://www.jto.org/article/S1556-0864(26)00007-9/fulltext [https://www.jto.org/article/S1556-0864(26)00007-9/fulltext]Post mortem sacituzumab govitecan study:https://pmc.ncbi.nlm.nih.gov/articles/PMC8495771/ [https://pmc.ncbi.nlm.nih.gov/articles/PMC8495771/]

Is HRR really a biomarker in prostate cancer?

Why HRR gene mutations are not the perfect biomarker. PROpel trial: thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00382-0/fulltext TALAPRO-2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract TRITON-3 trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2214676

Interpreting prospective ctDNA trials

Some thoughts on how to interpret ctDNA trials that look to validate it as a predictive biomarker

Why we should look at continuing CD38 antibodies after progression

There is an explosion of trials in the CD38 antibody space (daratumumab, isatuximab) in multiple myeloma. This episode goes over one key unanswered question which many of the trials are not attempting to answer.